Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1992-5-26
pubmed:abstractText
Antiphospholipid syndrome (APLS) is characterized by thrombocytopenia, thromboembolic phenomena, and recurrent fetal loss, associated with anticardiolipin antibodies (ACA) and/or lupus anticoagulant. The syndrome may be primary or may be associated with other conditions such as systemic lupus erythematosus. We have previously shown the ability to induce APLS in naive mice following passive transfer of serum and monoclonal ACAs. Similarly we generated the secondary APLS in BALB/c mice following immunization with a pathogenic anti-DNA antibody. In the current study we report on the induction of primary APLS following immunization of BALB/c mice with a human monoclonal ACA (H-3). The mice developed high persistent titers of ACA. The APLS was characterized by prolonged activated partial thromboplastin time, low fecundity rate (21% vs. 48% of control immunized mice), high resorption index of fetuses (25% vs. 3%), and low weights of embryos and placentae. Our study points to the ability of inducing primary APLS in naive mice. The induction of various presentations of APLS by different ACA may explain the diversity of clinical manifestations seen in patients with APLS.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/1569194-2014226, http://linkedlifedata.com/resource/pubmed/commentcorrection/1569194-2185781, http://linkedlifedata.com/resource/pubmed/commentcorrection/1569194-2197866, http://linkedlifedata.com/resource/pubmed/commentcorrection/1569194-2251509, http://linkedlifedata.com/resource/pubmed/commentcorrection/1569194-2405476, http://linkedlifedata.com/resource/pubmed/commentcorrection/1569194-2509856, http://linkedlifedata.com/resource/pubmed/commentcorrection/1569194-2656011, http://linkedlifedata.com/resource/pubmed/commentcorrection/1569194-2746588, http://linkedlifedata.com/resource/pubmed/commentcorrection/1569194-2789501, http://linkedlifedata.com/resource/pubmed/commentcorrection/1569194-3146452, http://linkedlifedata.com/resource/pubmed/commentcorrection/1569194-3258423, http://linkedlifedata.com/resource/pubmed/commentcorrection/1569194-3606679, http://linkedlifedata.com/resource/pubmed/commentcorrection/1569194-6139567, http://linkedlifedata.com/resource/pubmed/commentcorrection/1569194-6147499, http://linkedlifedata.com/resource/pubmed/commentcorrection/1569194-6199030, http://linkedlifedata.com/resource/pubmed/commentcorrection/1569194-6823251, http://linkedlifedata.com/resource/pubmed/commentcorrection/1569194-6886627, http://linkedlifedata.com/resource/pubmed/commentcorrection/1569194-7085884
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0021-9738
pubmed:author
pubmed:issnType
Print
pubmed:volume
89
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1558-63
pubmed:dateRevised
2010-9-7
pubmed:meshHeading
pubmed:year
1992
pubmed:articleTitle
Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3).
pubmed:affiliation
Department of Medicine B, Sheba Medical Center, Tel-Hashomer, Israel.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't